Drugs / WSK-V102
WSK-V102
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05765604 | Mar → Jul 2023 | COVID-19 | WestVac Biopharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WSK-V102 | “A Randomized, Parallel Controlled, Double-blind, Single-center Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)(WSK-V102) in People Aged 18 Years or Older” NCT05765604 ↗ |
| Known as | Recombinant variant COVID-19 vaccine (Sf9 cell)(WSK-V102) | “Recombinant variant COVID-19 vaccine (Sf9 cell)(WSK-V102)” NCT05765604 ↗ |